Nasal pharmacokinetic (PK)pharmacodynamic (PD) studies of oral combination products containing opioid agonists and antagonists

Ended Awarded Last action

Contract number
75F40118F01002
Awardee
Awarding agency
Obligated
$2,877,830

Award facts

Opportunity
Contract value 100% obligated
$2,877,830.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Columbia, MO 65201, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00012 · Update deliverable schedule $0
Funding Only Action P00011 · The purpose of this modification is to obligate additional funding and extend the period of performance. $69,565
Other Administrative Action P00010 $0
Other Administrative Action P00009 $0
Other Administrative Action P00008 $19,560
Other Administrative Action P00007 $0
Supplemental Agreement for work within scope P00006 $0
Other Administrative Action P00005 $999,305
Other Administrative Action P00004 · MOD 0004 to change the COR of record. $0
Other Administrative Action P00003 · MOD 0003 to add funding for in-scope changes and increased fees. $139,400
Exercise an Option P00002 $413,788
Supplemental Agreement for work within scope P00001 $0
Original award $1,236,212
Show all 13

About this award

Written by GovTribe AI ·

The Department of Health and Human Services Food and Drug Administration awarded a $2,877,830 firm fixed price delivery order contract to Biopharma Services USA Inc. for NASAL PHARMACOKINETIC (PK)PHARMACODYNAMIC (PD) STUDIES OF ORAL COMBINATION PRODUCTS CONTAINING OPIOID AGONISTS AND ANTAGONISTS. As a foreign owned, self-certified small disadvantaged business, Biopharma Services USA will conduct the in vivo study of generic drug products in human subjects to fulfill the FDA's major program of evaluating such combination opioid products. Performance will take place in Columbia, Missouri by July 2024. No set-aside designation was applied to this award.

Quick answers

Who was awarded contract 75F40118F01002?

75F40118F01002 was awarded to Biopharma Services USA by Food and Drug Administration (Department of Health and Human Services) on September 13, 2018.

How much is contract 75F40118F01002 worth?

The government has obligated $2,877,830 on 75F40118F01002.

Is contract 75F40118F01002 an order under another contract?

Yes. 75F40118F01002 is a delivery order under HHSF223201610004I, an indefinite delivery contract.

Was contract 75F40118F01002 competed?

The extent of competition for 75F40118F01002 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login